Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sacituzumab tirumotecan + bevacizumab in previously treated EGFR-mutant or other oncogenic variant advanced NSCLC
ChiCTR2500108997Phase 2Not yet recruiting
- Sponsor
- Henan Cancer Hospital
- Start
- Sep 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sacituzumab tirumotecan and bevacizumab in non-small cell lung cancer (NSCLC), sponsored by Henan Cancer Hospital. Primary endpoint: Objective Response Rate (ORR). Planned start Sep 2025; status: not yet recruiting.
02
Drugs
sacituzumab tirumotecanbevacizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2500108997.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500108997.